The agreement was signed following Foamix’s successful development of non-steroidal foam which is designed to help skin barrier properties.
Under the terms of the agreement, Foamix will be entitled to receive milestone payments upon achievement of various developments and commercial events and double-digit royalties.
James McMillan II, CEO of Ferndale, said: “We are pleased to announce this license agreement with Foamix. Foamix has a proven track record of developing innovative dermatological foams and we are confident that this innovative product is a valuable addition to Ferndale’s medications portfolio.”